Neuried, Germany
Neuried, Germany

Time filter

Source Type

The present invention relates to a method for the normalization of an immunological test characterized in that the presence of a comparable amount of cells is determined by a sandwich ELISA test wherein the capture antibody is at least one antibody which binds to at least one keratin selected from the group consisting of keratin 4, 5, 6, 8, 10, 13 and 18 and the detection antibody is at least one antibody which binds to said keratin.


Receive press releases from iHealthcareAnalyst, Inc.: By Email Hepatitis E Diagnostic Tests Market by Test Types, End Users, Growth Trends and Forecast to 2021, Upcoming Report by iHealthcareAnalyst, Inc. Hepatitis E Diagnostic Tests Market by Test Type (ELISA HEV IgM Test Kits, ELISA HEV IgG Test Kits, RT-PCR Test Kits, Others), End Users (Diagnostic Laboratories, Hospitals, Point-of-Care) and Forecast 2017-2021. Maryland Heights, MO, April 30, 2017 --( Browse Hepatitis E Diagnostic Tests Market by Test Type (ELISA HEV IgM Test Kits, ELISA HEV IgG Test Kits, RT-PCR Test Kits, Others), End Users (Diagnostic Laboratories, Hospitals, Point-of-Care) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/hepatitis-e-diagnostics-market/ The global hepatitis E diagnostic tests market segmentation is based on test type (ELISA HEV IgM test kits, ELISA HEV IgG test kits, RT-PCR test kits, Others), end users (diagnostic laboratories, hospitals, point-of-care). The global hepatitis E diagnostic tests market report provides market size (Revenue USD Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global hepatitis E diagnostic tests market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global hepatitis E diagnostic tests market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market. Major players operating in the global hepatitis E diagnostic tests market and profiled in this report include Altana Diagnostics GmbH, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Biokit S.A., Dia.Pro - Diagnostic Bioprobes s.r.l, F. Hoffmann-La Roche Ltd., Fast-track diagnostics Ltd., Fortress Diagnostics Limited, Mikrogen GmBH, MP Biomedicals, LLC, and Primerdesign Ltd. 1. Test Type 1.1. ELISA HEV IgM Test Kits 1.2. ELISA HEV IgG Test Kits 1.3. RT-PCR Test Kits 1.4. Others 2. End Users 2.1. Diagnostic Laboratories 2.2. Hospitals 2.3. Point-of-Care 2.4. Research Centers 3. Geography (Region, Country) 3.1. North America (U.S., Canada) 3.2. Latin America (Brazil, Mexico, Rest of LA) 3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU) 3.4. Asia Pacific (Japan, China, India, Rest of APAC) 3.5. Rest of the World 4. Company Profiles 4.1. Altana Diagnostics GmbH 4.2. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. 4.3. Biokit S.A. 4.4. Dia.Pro - Diagnostic Bioprobes s.r.l 4.5. F. Hoffmann-La Roche Ltd. 4.6. Fast-track diagnostics Ltd. 4.7. Fortress Diagnostics Limited 4.8. Mikrogen GmBH 4.9. MP Biomedicals, LLC 4.10. Primerdesign Ltd. To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/hepatitis-e-diagnostics-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, April 30, 2017 --( PR.com )-- Hepatitis E is a liver disease caused by the hepatitis E virus (HEV), and the infection is found worldwide but most common in developing countries with limited access to essential water, sanitation, hygiene and health services. The commonly used tests for HEV infection include detection of IgM and IgG anti-HEV antibodies and detection of HEV RNA. Diagnosis of hepatitis E infection is usually based on the detection of specific IgM antibodies (ELISA). Additional tests include reverse transcriptase polymerase chain reaction (RT-PCR) to detect the hepatitis E virus RNA in blood and/or stool samples, carried out in specialized laboratory facilities. Recently, a test for viral antigen detection in serum has been developed. Although several diagnostic assays for anti-HEV antibodies are available, they have undergone fairly limited testing and often provide discordant results, particularly for IgG antibodies. Improved validation of existing anti-HEV antibody assays or development of new assays with superior performance characteristics is urgently needed.Browse Hepatitis E Diagnostic Tests Market by Test Type (ELISA HEV IgM Test Kits, ELISA HEV IgG Test Kits, RT-PCR Test Kits, Others), End Users (Diagnostic Laboratories, Hospitals, Point-of-Care) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/hepatitis-e-diagnostics-market/The global hepatitis E diagnostic tests market segmentation is based on test type (ELISA HEV IgM test kits, ELISA HEV IgG test kits, RT-PCR test kits, Others), end users (diagnostic laboratories, hospitals, point-of-care).The global hepatitis E diagnostic tests market report provides market size (Revenue USD Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global hepatitis E diagnostic tests market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global hepatitis E diagnostic tests market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.Major players operating in the global hepatitis E diagnostic tests market and profiled in this report include Altana Diagnostics GmbH, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Biokit S.A., Dia.Pro - Diagnostic Bioprobes s.r.l, F. Hoffmann-La Roche Ltd., Fast-track diagnostics Ltd., Fortress Diagnostics Limited, Mikrogen GmBH, MP Biomedicals, LLC, and Primerdesign Ltd.1. Test Type1.1. ELISA HEV IgM Test Kits1.2. ELISA HEV IgG Test Kits1.3. RT-PCR Test Kits1.4. Others2. End Users2.1. Diagnostic Laboratories2.2. Hospitals2.3. Point-of-Care2.4. Research Centers3. Geography (Region, Country)3.1. North America (U.S., Canada)3.2. Latin America (Brazil, Mexico, Rest of LA)3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)3.4. Asia Pacific (Japan, China, India, Rest of APAC)3.5. Rest of the World4. Company Profiles4.1. Altana Diagnostics GmbH4.2. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.4.3. Biokit S.A.4.4. Dia.Pro - Diagnostic Bioprobes s.r.l4.5. F. Hoffmann-La Roche Ltd.4.6. Fast-track diagnostics Ltd.4.7. Fortress Diagnostics Limited4.8. Mikrogen GmBH4.9. MP Biomedicals, LLC4.10. Primerdesign Ltd.To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/hepatitis-e-diagnostics-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill DriveMaryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2012.2.3.0-1 | Award Amount: 4.57M | Year: 2012

The SMEs MIKROGEN and BIOSYNEX are well established in the field of diagnostic tests for infectious diseases in humans and perform active research into innovative products. As a critical step to get access to the lucrative market of diagnostic kits for the detection of persistent infections by human papillomaviruses (HPV), the SMEs teamed up with partner UIBK who developed a unique set of immunological tools suitable for this purpose, and two leading European gynecological clinics with longstanding interest in improving clinical management of HPV-associated diseases. Currently used diagnostic tools can detect HPV DNA in cervical smears but fall short of discriminating between transient infections which can spontaneously regress and persistent infections, which have a high chance to progress to high-grade squamous intraepithelial lesions. At this point, the PIPAVIR consortium comes in with the proposal to develop and validate a new diagnostic test for progressive infectious diseases that allows detection, by sandwich-ELISA, of HPV E7 proteins in cervical smears, as markers specific for persistent infections with bad prognosis. In addition, it is planned to develop and validate a diagnostic test strip for rapid detection of viral E7 proteins in cervical smears, most appropriate for alternative diagnostic procedures, such as self-sampling, as well as for the use in low-resource settings. As a major innovative feature, both proposed products use as molecular markers virus-encoded proteins closely related to infection-associated pathology, rather than just the presence of viral DNA or any surrogate markers. Based on the potential of the technology to meet a real clinical need, it can be anticipated that the ability of the participating SME partners to provide and market such superior diagnostic tools will create great business opportunities.


Krumbholz A.,Jena University Hospital | Mohn U.,Mikrogen GmbH | Lange J.,Jena University Hospital | Motz M.,Mikrogen GmbH | And 6 more authors.
Medical Microbiology and Immunology | Year: 2012

Due to the increasing number of non-travel-associated hepatitis E virus (HEV) infections observed in several industrialised countries including Germany, there is a substantial interest in the characterisation of risk factors and transmission routes relevant to autochthonous HEV infections. Autochthonous cases are believed to be the result of a zoonotic HEV transmission from pigs, wild boars and deer. Recently, a high prevalence of HEV-specific antibodies in the German domestic pig population has been demonstrated. Thus, one may assume a higher prevalence of HEV-specific antibodies in humans with occupational exposure to pigs. In this study, sera obtained from 24 slaughterers, 14 meat inspectors, 46 pig farmers and 22 veterinarians were tested for the presence of HEV-specific antibodies using a line immunoassay. For comparison, sera obtained from 116 age- and gender-matched blood donors were also included. Twenty eight per cent (28.3%; 30/106) of the swine-exposed humans and 15.5% (18/116) of the blood donors without contact to pigs exhibited IgG-antibodies determined as reactive (i.e. borderline or positive) against HEV. Thus, an increased risk of HEV infection in humans occupationally exposed to pigs and particularly for slaughterers (41.7%; 10/24) was demonstrated. © Springer-Verlag 2011.


Bohm B.,Albert Ludwigs University of Freiburg | Heinzelmann S.,Albert Ludwigs University of Freiburg | Motz M.,Mikrogen GmbH | Bauer G.,Albert Ludwigs University of Freiburg
Biological Chemistry | Year: 2015

Oncogenic transformation is dependent on activated membrane-associated NADPH oxidase (NOX). However, the resultant extracellular superoxide anions are also driving the NO/peroxynitrite and the HOCl pathway, which eliminates NOX-expressing transformed cells through selective apoptosis induction. Tumor progression is dependent on dominant interference with intercellular apoptosis-inducing ROS signaling through membrane-associated catalase, which decomposes H2O2 and peroxynitrite and oxidizes NO. Particularly, the decomposition of extracellular peroxynitrite strictly requires membrane-associated catalase. We utilized small interfering RNA (siRNA)-mediated knockdown of catalase and neutralizing antibodies directed against the enzyme in combination with challenging H2O2 or peroxynitrite to determine activity and localization of catalase in cells from three distinct steps of multistage oncogenesis. Nontransformed cells did not generate extracellular superoxide anions and only showed intracellular catalase activity. Transformed cells showed superoxide anion-dependent intercellular apoptosis-inducing ROS signaling in the presence of suboptimal catalase activity in their membrane. Tumor cells exhibited tight control of intercellular apoptosis-inducing ROS signaling through a high local concentration of membrane-associated catalase. These data demonstrate that translocation of catalase to the outside of the cell membrane is already associated with the transformation step. A strong local increase in the concentration of membrane-associated catalase is achieved during tumor progression and is controlled by tumor cell-derived H2O2 and by transglutaminase. © 2015 by De Gruyter.


Bauer G.,Albert Ludwigs University of Freiburg | Motz M.,Mikrogen GmbH
Anticancer Research | Year: 2016

Neutralizing single-domain antibodies directed towards catalase or superoxide dismutase (SOD) caused efficient reactivation of intercellular reactive oxygen species/reactive nitrogen species (ROS/RNS)-dependent apoptosis-inducing signaling specifically in human tumor cells. Single-domain antibodies targeted tumor cell-specific membrane-associated SOD and catalase, but not the corresponding intracellular enzymes. They were shown to be about 200-fold more effective than corresponding classical recombinant antigen-binding fragments and more than four log steps more efficient than monoclonal antibodies. Combined addition of single-domain antibodies against catalase and SOD caused a remarkable synergistic effect. Proof-of-concept experiments in immunocompromised mice using human tumor xenografts and single-domain antibodies directed towards SOD showed an inhibition of tumor growth. Neutralizing single-domain antibodies directed to catalase and SOD also caused a very strong synergistic effect with the established chemotherapeutic agent taxol, indicating an overlap of signaling pathways. This effect might also be useful in order to avoid unwanted side-effects and to drastically lower the costs for taxol-based therapy.


Devices are disclosed for serologically detecting an infection with human-pathogenic Yersinia ssp, wherein said device comprises at least one antigen selected from the group of antigens consisting of the following group: YopD, YopH, YopM, YopE, V-AG and YopN or a fragment of one of said antigens having at least eight consecutive amino acids and furthermore one of two proteins selected from MyfA and PsaA or fragments of one of said two proteins having at least eight consecutive amino acids.


The present invention relates to a diagnostic test for the detection of an E7 protein of a human papilloma virus in a biological sample wherein a sandwich ELISA as capture antibody at least two different rabbit monoclonal antibodies which bind to at least two different epitopes are used and as detection antibody at least two different polyclonal anti E7 antibodies are used.


Trademark
Mikrogen GmbH | Date: 2012-11-06

Diagnostic agents, namely, reagents and diagnostic preparations for scientific purposes; biochemical agents and preparations, namely, reagents, for scientific purposes, in particular recombinantly produced proteins and peptides; chemical and biochemical reagents and genetic identity tests comprised of reagents for the identification of DNA by means of PCR technology and hybridization. Diagnostic agents, for medical and pharmaceutical purposes, namely, medical diagnostic reagents and radioactive pharmaceutical preparations for in vivo diagnostic use; biochemical agents and preparations for pharmaceutical purposes, namely, pharmaceuticals for use in diagnosing bacterial and viral infectious diseases and autoimmune diseases; diagnostic agents for medical purposes, namely, recombinantly or synthetically produced antigens for medical, in particular diagnostic purposes; diagnostic agents for medical purposes, namely, lysates of microorganisms, in particular preparations of components of microorganisms usable for diagnostic purposes; diagnostic agents for carrying out serologic tests for medical purposes; biochemical preparations for carrying out verification tests for medical purposes, namely, diagnosis of bacterial and viral infectious diseases and autoimmune diseases ; diagnostic preparations for medical use, namely, diagnostic preparations for carrying out western blot tests for medical purposes; diagnostic preparations for medical use, namely, diagnostic preparations for carrying out enzyme immune tests for medical purposes; diagnostic reagents for serologic test of infections for medical purposes. Services of a medical, bacteriological and biochemical laboratory, in particular chemical synthesis of oligonucleotides; scientific analysis regarding reagents and probes for the identification of DNA by means of PCR technology and hybridization; research and development services in the field of bacteriology, cytology, antibody technology, chemistry, immunology and gene expression systems, in particular regarding cloning, expression and purification of proteins and antigens for third parties; biochemical research and development for recombinant production of partially purified proteins of microorganisms.


Driven by a small number of players, the global market for Hepatitis E Diagnostic Tests exhibits a highly competitive landscape, finds a new report by Transparency Market Research (TMR). With a share of nearly 31%, Beijing Wantai Biological Pharmacy led the global market in 2015 and was distantly followed by Mikrogen. Competitive pricing strategy among the leading players is expected to intensify the rivalry within the market in the forthcoming years. According to the research report, the global hepatitis E diagnostic tests market stood at US$43.7 mn in 2015. Expanding at a CAGR of 3.80% during the period from 2016 to 2024, the opportunity in this market is likely to increase to US$60.4 mn by the end of the forecast period. Being the primary test for the detection of hepatitis E, the kits used for ELISA HEV IgM tests have been the most valued diagnostic kits in this market in the recent past and will continue to be so due to the same reason. Hepatitis E Hyperendemicity in Asian Economies to Ensure Dominance of Asia Pacific Region The research report has also analyzed the worldwide market for hepatitis E diagnostic tests on the basis of geography. According to the study, Europe, Asia Pacific, Latin America, North America, and the Middle East and Africa have surfaced as the main regional markets for hepatitis E diagnostic tests across the world. Due to the hyperendemicity of hepatitis E in various Asian economies, such as Nepal, Pakistan, India, Vietnam, Bangladesh, Bhutan, Burma, Kazakhstan, and Thailand, Asia Pacific has surfaced as the leading regional market for hepatitis E diagnostic tests and is expected to remain so over the forecast period. The Asia Pacific market for hepatitis E diagnostic tests is likely to acquire more than 48% of the overall market by 2024. Besides, the Middle East and Africa is also projected to witness a significant rise in the market for the hepatitis E diagnostic tests over the next few years due to the increasing prevalence of hepatitis E in various countries in this region, such as Kenya, Morocco, Uganda, and Nigeria, owing to lack of safe drinking water and poor sanitation facilities. "The growth of the global market for hepatitis E is directly proportional to the prevalence of hepatitis E across the world," says the author of this study. As per the WHO, nearly 20 million people suffer from HEV infections every year, worldwide, among which around 3.3 million are symptomatic cases. With the increasing scarcity of potable water and the lack of sanitation, the cases of hepatitis E infection is likely to increase considerably over the forthcoming years and will result in a substantial rise in the need for hepatitis E diagnostic test in the near future, states the research report. Although the worldwide market for hepatitis E diagnostic tests currently looks teeming with opportunity, it may face a severe challenge over the years to come from the rising incidence of asymptomatic diseases, which are difficult to diagnose. The low level of awareness among consumers is also expected to emerge as a restraining factor for the growth of this market in the long run, notes the study. The study presented here is based on a report by Transparency Market Research (TMR) titled "Hepatitis E Diagnostic Tests Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024." The Hepatitis E Diagnostic Tests Market has been segmented as follows: Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Loading Mikrogen GmbH collaborators
Loading Mikrogen GmbH collaborators